BIOENGINEERED STRUCTURE BASED ON BACTERIAL ALGINATE AND PROBIOTIC BACTERIA AND METHOD FOR PRODUCTION THEREOF Russian patent published in 2021 - IPC A61K47/32 A61K9/52 A61P43/00 C12N1/20 

FIELD: medicine; pharmaceuticals.

SUBSTANCE: invention relates to medicine and pharmaceutics, in particular to an article for treating and creating experimental models of gastrointestinal disorders, due to the therapeutic action of living probiotic bacteria cultivated in situ in a bioengineering structure. Disclosed is a bioengineering structure for probiotic bacteria of genera Lactobacillus and Bifidobacterium, which is a layer of porous microspheres in a hydrogel arranged on a porous substrate. Porous substrate is made from poly-3-oxybutyrate and/or its copolymer with 3-oxyvalerate with molecular weight from 1 × 10⁵ to 2 × 10⁶ g/mol and is characterized by the presence of through pores (or bonded pores), total porosity from 75 to 99 %, average pore diameter from 0.5 to 20 mcm. Porous microspheres are made from poly-3-oxybutyrate with molecular weight from 1 × 10⁴ to 1 × 10⁶ g/mol and are characterized by availability of through pores (or connected pores), total porosity from 75 to 99 %, average pore diameter from 0.5 to 20 mcm. Pores of substrate and microspheres are filled with hydrogel containing probiotic bacteria. Hydrogel is made from bacterial alginate with molecular weight from 10⁵ to 10⁶ g/mol, molar content of guluronic acid residues in polymer from 31 mol. % to 48 mol. % and acetylation level is from 10 mol. % to 46 mol. %. Besides, a method of producing the above bioengineered structure is proposed.

EFFECT: technical result is obtaining a hybrid bioengineering structure based on probiotic bacteria and bacterial polymers (poly-3-oxyalkanoate and alginate), providing at least 95 % survival rate of bacteria, as well as increasing their protection (increase in bacteria survival by at least 50 %) in an unfavorable medium while preserving biocompatibility (no cytotoxicity) of the construct in vitro.

18 cl, 2 dwg, 4 ex